Botulinum Toxin Type A
Indication
Focal Spasticity in Multiple Sclerosis
Multiple sclerosis in adults: management (NICE CG186)
NICE Pathway - Spasticity in children and young people overview
Red
Brand:
All brands within licensed indications only
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Central nervous system
Background
NICE CG186 does not make a recommendation on use of botulinum toxin A for spasticity in MS . Use has been approved locally after a review of audit data, provided:
- treatment is restricted to those patients who have failed or could not have other treatments
- treatment is only initiated by an appropriate specialist with experience in use of botulinum toxin A, that there are clearly defined goals of treatment — set prior to initiation and against which patients will be reviewed at each injection cycle.